Life Science Sweden: Det svenska bioteknikföretaget Asarina har beviljats USA-patent för sin läkemedelskandidat Sepranolon som behandling av Tourettes syndrom, tvångssyndrom och sjukligt spelberoende.
Asarina Pharma science and business in the media
Financial Hearings host a Digital R&D Day. Explore the key four metrics of Asarina Pharma’s Phase IIb trial with our CEO, CSO, COO, PMDD KOL Dr Paula Briggs and Asarina Pharma communications expert Olivia Hahne.
Bolaget som prickat in hälsovårdstrenderna, EFN.
Handelsbanken hälsovård expert Astrid Samuelsson: “Asarina har ett väldigt intressant år framför sig, med data från flera studier som bli färdiga”
The ‘Severest Form of PMS’ Could Finally Get a Treatment
Trials have just started for the first drug to treat premenstrual dysphoric disorder, a debilitating condition still ignored by some doctors.
Fråga doktorn: Mens (Ask the doctor: Periods)
Asarina Scientific Advisory Board member Prof Marie Bixo on Swedish TV’s peak-time medical Q&A programme.
Swedish national neurology news site notes first enrolment in Asarina’s Phase II menstrual migraine study.
The condition making women feel suicidal every month
‘How Liverpool could be the place to solve it – landmark treatment trial taking place in city’
Asarina Pharma: DNB höjer riktkursen till 44 KR (37) (DNB increases target share value to 44 SEK)
Swedish investor site on increased valuation of Asarina Pharma.
PMDS: Förekomst, symptom, uttryck och behandling (PMDD: Prevention, symptoms, prevalence and treatment)
CSO Torbjörn Bäckström, on Swedish educational TV channel UR Play, lectures on PMDD triggers and treatment. Plus audience Q&A.
Svenska forskare: Medicin finns snart mot svår PMDS (Swedish researchers: Treatment soon available for PMDD)
CSO Prof Torbjörn Bäckström and COO Karin Ekberg interviewed by Swedish tabloid Expressen.
Premenstrual Dysphoric Disorder (PMDD)
UK’s premier women’s issue radio programme covers PMDD and Phase IIb trial for new treatment.
Många lider i tysthet av svår PMS: ”Ett allvarligt handikapp” (Many suffer in silence from extreme PMS)
CSO Prof Torbjörn Bäckström interviewed by Sweden’s largest TV News service.
Därför måste vi prata mer om PMS och PMDS (Why we need to talk more about PMS & PMDD)
Swedish mobile news and lifestyle site on PMS, PMDD and Asarina Pharma’s new treatment.
Asarina Pharma: Mycket forskning för pengarna (Asarina Pharma: A lot of research for your money)
Swedish investor paper’s positive report on Asarina Pharma.
Bioteknikbolaget Asarina Pharma tar sikte på USA (Biotech company Asarina Pharma targets US)
Sweden’s largest business news channel interviews CEO Peter Nordkild.
Asarina Pharma en bra lottsedel för bioteknikfans (Asarina Pharma a safe bet for biotech fans)
Swedish investor paper’s positive report on Asarina Pharma.
Märta Segerdahl ny CMO på Asarina Pharma (Märta Segerdahl Apponted New CMO for Asarina Pharma)
Swedish pharma industry news service interview Asarina Pharma’s new Chief Medical Officer.
Får finansiering för studie på svår PMS (Funding received for severe PMS)
Swedish Life Science magazine on Asarina Pharma earning funding for its Phase IIb Study.
Forskare ger inte upp kampen mot svår pms (Researchers refuse to give up fight against severe PMS)
Swedish medical and lifestyle site on Asarina Pharma’s upcoming new Phase IIb PMDD Study.